Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Tscharre M., Vogel B., Tentzeris I., Freynhofer M. K., Rohla M., Wojta J., Weiss T. W., d m. n. A. D., Huber K., Farhan S.
Thrombosis and Haemostasis
Vol.119, Issue2, P. 340-347
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1055/s-0038-1676563
Аннотация:
Background Soluble P-selectin (sP-selectin), a biomarker of inflammatory pathologies including cardiovascular disease, is known to have pro-atherosclerotic effects such as the ability to increase leukocyte recruitment and modulate thrombotic response. We aimed to assess the impact of sP-selectin on long-term major adverse cardiovascular events (MACE) in patients after coronary stenting for coronary artery disease. Methods We analysed 733 patients of a single-centre registry undergoing percutaneous coronary intervention (PCI) between 2003 and 2006. Plasma samples were analysed for sP-selectin antigen concentration with an enzyme-linked immunoassay. The study population was categorized according to sP-selectin quartiles. Endpoint of the study was long-term MACE, a composite of all-cause death, myocardial infarction (MI) and stroke. Results Of the total patient cohort, 361 (49.2[%]) patients were admitted for stable coronary artery disease and 372 (50.8[%]) for acute coronary syndrome. Median
Ключевые слова:
long-term major adverse cardiovascular outcome; percutaneous coronary intervention; soluble P-selectin
angiotensin receptor antagonist; beta adrenergic receptor blocking agent; PADGEM protein; statin (protein); troponin I; biological marker; PADGEM protein; SELP protein, human; acute coronary syndrome; adult; aged; all cause mortality; Article; brain ischemia; cardiovascular disease; cardiovascular risk; cerebrovascular accident; cohort analysis; controlled study; coronary angiography; coronary artery disease; coronary stenting; enzyme linked immunosorbent assay; estimated glomerular filtration rate; female; follow up; heart infarction; hospitalization; human; hyperlipidemia; hypertension; major clinical study; male; middle aged; percutaneous coronary intervention; priority journal; blood; complication; coronary artery disease; heart infarction; inflammation; percutaneous coronary intervention; prognosis; prospective study; register; stent; Aged; Biomarkers; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; My
Язык текста: Английский
ISSN: 0340-6245
Tscharre M.
Vogel B.
Tentzeris I.
Freynhofer M. K.
Rohla M.
Wojta J.
Weiss T. W.
m. n. A. D. m n Ay Dzhikhan 1980-
Huber K.
Farhan S.
Цчарре М.
Вогел Б.
Тентзерис И.
Фреyнхофер М. К.
Рохла М.
Wойта Й.
Wеисс Т. W.
м. н. А. Д. м н Ай Джихан 1980-
Хубер К.
Фархан С.
Prognostic Impact of Soluble P-Selectin on Long-Term Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Текст визуальный непосредственный
Thrombosis and Haemostasis
Schattauer
Vol.119, Issue2 P. 340-347
2019
Статья
long-term major adverse cardiovascular outcome percutaneous coronary intervention soluble P-selectin
angiotensin receptor antagonist beta adrenergic receptor blocking agent PADGEM protein statin (protein) troponin I biological marker PADGEM protein SELP protein, human acute coronary syndrome adult aged all cause mortality Article brain ischemia cardiovascular disease cardiovascular risk cerebrovascular accident cohort analysis controlled study coronary angiography coronary artery disease coronary stenting enzyme linked immunosorbent assay estimated glomerular filtration rate female follow up heart infarction hospitalization human hyperlipidemia hypertension major clinical study male middle aged percutaneous coronary intervention priority journal blood complication coronary artery disease heart infarction inflammation percutaneous coronary intervention prognosis prospective study register stent Aged Biomarkers Coronary Artery Disease Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Humans Inflammation Male Middle Aged My
Background Soluble P-selectin (sP-selectin), a biomarker of inflammatory pathologies including cardiovascular disease, is known to have pro-atherosclerotic effects such as the ability to increase leukocyte recruitment and modulate thrombotic response. We aimed to assess the impact of sP-selectin on long-term major adverse cardiovascular events (MACE) in patients after coronary stenting for coronary artery disease. Methods We analysed 733 patients of a single-centre registry undergoing percutaneous coronary intervention (PCI) between 2003 and 2006. Plasma samples were analysed for sP-selectin antigen concentration with an enzyme-linked immunoassay. The study population was categorized according to sP-selectin quartiles. Endpoint of the study was long-term MACE, a composite of all-cause death, myocardial infarction (MI) and stroke. Results Of the total patient cohort, 361 (49.2[%]) patients were admitted for stable coronary artery disease and 372 (50.8[%]) for acute coronary syndrome. Median